skip to content

New data show Roche’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)

Investors

Investor updates
view all

stay updated

get the latest news and updates to your inbox.